Press Release: Novartis ianalumab Phase III trial -2-

Novartis

97.51 CHF -0.45%

• Charts
• News
• Analysen

Kaufen Verkaufen

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Novartis. Data on file.

2. Clinicaltrials.gov. NCT05653219. A Study of Efficacy and Safety of

Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune

Thrombocytopenia Patients Who Failed Steroids (VAYHIT2). Accessed July

21, 2025. https://clinicaltrials.gov/study/NCT05653219

3. Clinicaltrials.gov. NCT05653349. Study of Ianalumab Versus Placebo in

Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia

(ITP) (VAYHIT1). Accessed July 21, 2025.

https://clinicaltrials.gov/study/NCT05653349

4. Clinicaltrials.gov. NCT05648968. A Study of Efficacy and Safety of

Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic

Anemia (VAYHIA) Accessed July 21, 2025.

https://clinicaltrials.gov/study/NCT05648968

5. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of

terminology, definitions and outcome criteria in immune thrombocytopenic

purpura of adults and children: report from an international working

group. Blood. 2009;113(11):2386-2393. doi:10.1182/blood-2008-07-162503

6. Kuter DJ, Mathias SD, Rummel M, et al. Health-related quality of life in

nonsplenectomized immune thrombocytopenia patients receiving romiplostim

or medical standard of care. Am J Hematol. 2012;87:558-61

7. Kuter DJ. The treatment of immune thrombocytopenia (ITP)--focus on

thrombopoietin receptor agonists. Ann Blood. 2021;6:27.

doi:10.21037/aob-2021-itp-04

8. Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, et al. Novel

therapies to address unmet needs in ITP. Pharmaceuticals (Basel).

2022;15(7):779. doi:10.3390/ph15070779

9. US Food and Drug Administration. Orphan drug designation:

ianalumab--treatment of primary immune thrombocytopenia. Published

February 13, 2025. Accessed August 9, 2025.

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1018924

10. European Commission. Community register of orphan medicinal products:

ianalumab. Updated June 30, 2025. Accessed August 9, 2025.

https://ec.europa.eu/health/documents/community-register/html/o3036.htm

11. Dörner T, Bowman SJ, Fox R, et al. Safety and Efficacy of Ianalumab

in Patients With Sjögren's Disease: 52-Week Results From a

Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study. Arthritis

Rheumatol. 2025;77(5):560-570. doi:10.1002/art.43059

12. Clinicaltrials.gov. NCT05350072. Two-arm Study to Assess Efficacy and

Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

(NEPTUNUS-1). Accessed August 9, 2025.

https://clinicaltrials.gov/study/NCT05350072

13. Clinicaltrials.gov. NCT05349214. Three-arm Study to Assess Efficacy and

Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

(NEPTUNUS-2). Accessed August 9, 2025.

https://clinicaltrials.gov/study/NCT05349214

14. Clinicaltrials.gov. NCT05639114. Phase 3 Study to Evaluate Two Regimens

of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic

Lupus Erythematosus (SIRIUS-SLE 1) (SIRIUS-SLE 1). Accessed August 9,

2025. https://www.clinicaltrials.gov/study/NCT05639114

15. Clinicaltrials.gov. NCT05126277. Safety, Efficacy and Tolerability of

Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants

With Active Lupus Nephritis (SIRIUS-LN). Accessed August 9, 2025.

https://clinicaltrials.gov/study/NCT05126277

16. Clinicaltrials.gov. NCT06470048. A Clinical Study to Evaluate Ianalumab

in Participants With Diffuse Cutaneous Systemic Sclerosis. Accessed

August 9, 2025. https://clinicaltrials.gov/study/NCT06470048

17. Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of

subcutaneous ianalumab (VAY736) in patients with primary Sjögren's

syndrome: a randomised, double-blind, placebo-controlled, phase 2b

dose-finding trial. Lancet. 2022;399(10320):161-171.

doi:10.1016/S0140-6736(21)02251-0

18. Shen N, Ignatenko S, Gordienko A, et al. Phase 2 Safety and Efficacy of

Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered

Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE)

of Moderate-to-Severe Activity [abstract]. Arthritis Rheumatol. 2023; 75

(suppl 9). Accessed August 9, 2025.

https://acrabstracts.org/abstract/phase-2-safety-and-efficacy-of-subcutaneous-s-c-dose-ianalumab-vay736-anti-baffr-mab-administered-monthly-over-28-weeks-in-patients-with-systemic-lupus-erythematosus-sle-of-moderate-to-severe/

19. Bradbury C, Elverdi T, Trautmann K, et al. A phase 2 study of ianalumab

in patients with primary immune thrombocytopenia previously treated with

at least two lines of therapy (VAYHIT3). HemaSphere.

2025;9(Suppl 1):Abstract S238. Presented at European Hematology

Association (EHA) Congress, June 12--15, 2025. Milan, Italy. Accessed

August 9, 2025.

https://library.ehaweb.org/eha/2025/eha2025-congress/4159389/charlotte.bradbury.a.phase.2.study.of.ianalumab.in.patients.with.primary.html

20. Novartis. Press release. Novartis to strengthen oncology pipeline with

agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of

EUR 2.7bn in cash. February 5, 2024. Accessed August 9, 2025.

https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash

21. Provan D, Newland AC. Current management of primary immune

thrombocytopenia. Adv Ther. 2015;32(10):875-887.

doi:10.1007/s12325-015-0240-z

22. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World

Impact Survey (I-WISh): impact of ITP on health-related quality of life.

Am J Hematol. 2021;96(2):199-207. doi:10.1002/ajh.26083

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

August 12, 2025 01:15 ET (05:15 GMT)